QC
ASMB icon

Quadrature Capital’s Assembly Biosciences ASMB Stock Holding History

Quadrature Capital’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-17,935
Closed -$459K – 1253
2025
Q3 		$459K Buy
+17,935
New +$394K 0.01% 547

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Quadrature Capital's ASMB Position: Q4 2025 in Review

Quadrature Capital sold out of Assembly Biosciences (ASMB) in Q4 2025, closing a stake of 17,935 shares — an estimated $459K sold.

Quadrature Capital first reported a position in ASMB in Q3 2025 and held it in 1 quarter. The position peaked at $459K in Q3 2025. 69 funds tracked by Wall St. Rank hold ASMB as of Q4 2025.

  • Quadrature Capital reported no remaining Assembly Biosciences position as of Q4 2025 after selling out during the quarter.
  • Quadrature Capital sold 17,935 Assembly Biosciences shares in Q4 2025, an estimated $459K.
  • Quadrature Capital first reported a position in Assembly Biosciences in Q3 2025 and held it in 1 quarter.
  • Quadrature Capital's Assembly Biosciences position peaked at $459K in Q3 2025.
  • 69 funds tracked by Wall St. Rank held Assembly Biosciences as of Q4 2025.

Based on Quadrature Capital's 13F filing for Q4 2025, filed 17 Feb 2026.